Alchemab Therapeutics

Pharma executives no longer ask whether AI is important in their industry – that much is certain, and it is already ubiquitous. As Lamine Mbow , global head of discovery research at Boehringer Ingelh

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Lilly Partners With UK’s Alchemab On A

There has been an uptick in investor interest in non-oncology therapy areas in the past couple of years, with neuroscience again becoming a hot area, but biotechs in the space are finding that access

After a six-month search to find a permanent replacement for research chief John Reed, Sanofi has dipped into the venture capital sector and appointed Houman Ashrafian as its new head of R&D, effect